Moderna (MRNA) Capital Leases: 2017-2025
Historic Capital Leases for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $26.0 million.
- Moderna's Capital Leases fell 95.84% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year decrease of 95.84%. This contributed to the annual value of $39.0 million for FY2024, which is 93.22% down from last year.
- Moderna's Capital Leases amounted to $26.0 million in Q3 2025, which was down 18.75% from $32.0 million recorded in Q2 2025.
- In the past 5 years, Moderna's Capital Leases ranged from a high of $922.0 million in Q3 2022 and a low of $26.0 million during Q3 2025.
- Over the past 3 years, Moderna's median Capital Leases value was $575.0 million (recorded in 2024), while the average stood at $430.2 million.
- In the last 5 years, Moderna's Capital Leases skyrocketed by 444.55% in 2021 and then slumped by 95.84% in 2025.
- Moderna's Capital Leases (Quarterly) stood at $599.0 million in 2021, then spiked by 52.25% to $912.0 million in 2022, then slumped by 36.95% to $575.0 million in 2023, then plummeted by 93.22% to $39.0 million in 2024, then crashed by 95.84% to $26.0 million in 2025.
- Its Capital Leases stands at $26.0 million for Q3 2025, versus $32.0 million for Q2 2025 and $35.0 million for Q1 2025.